Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis.

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis.

<h4>Objectives</h4>5-aminosalicylate (mesalazine; 5-ASA) is an established first-line treatment for mild-to-moderate ulcerative colitis (UC). This study aimed to model the benefits of optimising 5-ASA therapy.<h4>Methods</h4>A decision tree mod...

Full description

Bibliographic Details
Main Authors: Louis, E, Paridaens, K, Al Awadhi, S, Begun, J, Cheon, JH, Dignass, AU, Magro, F, Márquez, JR, Moschen, AR, Narula, N, Rydzewska, G, Freddi, MJ, Travis, SP
Format: Journal article
Language:English
Published: BMJ Publishing Group 2022

Similar Items

Similar Items